Department of General Surgery, Digestive Disease Hospital, Affiliated Hospital of Zunyi Medical University, Zunyi, China.
Department of Oncology, Guizhou Provincial People's Hospital, Guiyang, China.
Immun Inflamm Dis. 2023 Nov;11(11):e1067. doi: 10.1002/iid3.1067.
Colorectal cancer (CRC) represents a leading cause of cancer-related deaths. Metronidazole (MNZ) is exceedingly implicated in CRC. This study explored the roles of MNZ in mouse CRC occurrence and liver metastasis (CRLM).
Male BALB/c nude mice were subjected to CRC and CRLM modeling, orally administration with MNZ (1 g/L) 1 week before modeling, and disease activity index (DAI) evaluation. Fresh stool and anal swab samples were collected on the morning of the 28th day after modeling. The relative expression of Fusobacterium nucleatum (F. nucleatum) DNA was assessed by quantitative polymerase chain reaction. After euthanasia, tumor tissues and liver tissues were separated and the tumor volume and weight change were measured. The liver tissues were stained with hematoxylin-eosin to quantitatively analyze the metastatic liver nodules. Malignant tumor biomarker Ki67 protein levels in liver tissues/DNA from stool samples were detected by immunohistochemistry/high-throughput 16S rRNA gene sequencing. Bioinformatics analysis was performed on the raw sequence data to analyze microbial community richness (Chao1 index, ACE index) and microbial community diversity (Shannon index).
The DAI and F. nucleatum DNA relative expression in feces and anal swabs of the CRC and CRLM groups were raised and repressed after MNZ intervention. MNZ repressed tumor occurrence and growth in mice to a certain extent, alleviated CRLM malignant degree (reduced liver metastases and Ki67-positive cell density/number), and suppressed CRC liver metastasis by regulating intestinal flora structure, which affected the intestinal characteristic flora of CRC and CRLM mice.
MNZ suppressed CRC occurrence and CRLM in mice by regulating intestinal F. nucleatum.
结直肠癌(CRC)是癌症相关死亡的主要原因。甲硝唑(MNZ)与 CRC 密切相关。本研究探讨了 MNZ 在小鼠 CRC 发生和肝转移(CRLM)中的作用。
雄性 BALB/c 裸鼠进行 CRC 和 CRLM 建模,建模前 1 周口服 MNZ(1g/L),并进行疾病活动指数(DAI)评估。建模后第 28 天早上采集新鲜粪便和肛门拭子样本。通过定量聚合酶链反应评估产黑色素拟杆菌(F. nucleatum)DNA 的相对表达。安乐死后,分离肿瘤组织和肝脏组织,测量肿瘤体积和重量变化。肝脏组织用苏木精-伊红染色,定量分析转移性肝结节。通过免疫组织化学/高通量 16S rRNA 基因测序检测肝组织/粪便样本中恶性肿瘤标志物 Ki67 蛋白水平。对原始序列数据进行生物信息学分析,分析微生物群落丰富度(Chao1 指数、ACE 指数)和微生物群落多样性(Shannon 指数)。
CRC 和 CRLM 组的 DAI 和粪便及肛门拭子中 F. nucleatum DNA 的相对表达在 MNZ 干预后升高和降低。MNZ 在一定程度上抑制了小鼠肿瘤的发生和生长,减轻了 CRLM 的恶性程度(减少了肝转移和 Ki67 阳性细胞密度/数量),并通过调节肠道菌群结构抑制了 CRC 的肝转移,影响了 CRC 和 CRLM 小鼠的肠道特征菌群。
MNZ 通过调节肠道 F. nucleatum 抑制了小鼠 CRC 的发生和 CRLM。